Epidemiological and Demographic Study of Patients with Mucormycosis and COVID-19
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Coronavirus disease 2019 (COVID-19) is associated with many bacterial and fungal diseases. Aspergillus and Candida have been reported as major pathogens resulting to comorbid infections in COVID-19 patients. Objective: Recent studies have shown a considerable burden of cases affected by mucormycosis after coronavirus disease 2019 (COVID-19) infection worldwide, and some underlying factors may contribute to this condition. Hence, this study aimed to investigate the epidemiology and demographic characteristics of mucormycosis patients after COVID-19 infection in the Ahvaz province of Iran. Methods: This descriptive-analytical epidemiological study was conducted on patients who developed mucormycosis following COVID-19 for a 6-month period in 2021. A checklist based on symptoms and possible risk factors was used to collect patient information. Results: The results showed that conjunctivitis, ophthalmalgia, facial swelling, feeling of pain or pressure in the face, and sinusitis were the most common clinical manifestations of patients with mucormycosis following COVID-19. Additionally, there was a significant association between corticosteroid and prophylactic antibiotic use, pain or pressure in the face, and ophthalmalgia with the outcome variables including alive or dead (p-values = 0.002, 0.011, 0.034, and 0.004, respectively). No statistically significant difference was found between the ages of the two groups (p-value = 0.495). Conclusion: The study findings revealed that the most common risk factors for mortality include diabetes, immune system defects, and use of prophylactic antibiotics or corticosteroids.
Abstract
Background: Coronavirus disease 2019 (COVID-19) is associated with many bacterial and fungal diseases. Aspergillus and Candida have been reported as major pathogens resulting to comorbid infections in COVID-19 patients. Objective: Recent studies have shown a considerable burden of cases affected by mucormycosis after coronavirus disease 2019 (COVID-19) infection worldwide, and some underlying factors may contribute to this condition. Hence, this study aimed to investigate the epidemiology and demographic characteristics of mucormycosis patients after COVID-19 infection in the Ahvaz province of Iran. Methods: This descriptive-analytical epidemiological study was conducted on patients who developed mucormycosis following COVID-19 for a 6-month period in 2021. A checklist based on symptoms and possible risk factors was used to collect patient information. Results: The results showed that conjunctivitis, ophthalmalgia, facial swelling, feeling of pain or pressure in the face, and sinusitis were the most common clinical manifestations of patients with mucormycosis following COVID-19. Additionally, there was a significant association between corticosteroid and prophylactic antibiotic use, pain or pressure in the face, and ophthalmalgia with the outcome variables including alive or dead (p-values = 0.002, 0.011, 0.034, and 0.004, respectively). No statistically significant difference was found between the ages of the two groups (p-value = 0.495). Conclusion: The study findings revealed that the most common risk factors for mortality include diabetes, immune system defects, and use of prophylactic antibiotics or corticosteroids.
참고문헌 (21)
- Rawson TM, "Understanding the role of bacterial and fungal infection in COVID-19", Clin Microbiol Infect, 27, pp.9~11 (2021)
- Zhou P, "Bacterial and fungal infections in COVID-19 patients : a matter of concern", Infect Control Hosp Epidemiol, 41, pp.1124~1125 (2020)
- Bhatt K, "High mortality co-infections of COVID-19 patients : mucormycosis and other fungal infections", Discoveries(Craiova), 9, pp.e126~ (2021)
- Song G, "Fungal co-infections associated with global COVID-19 pandemic : A clinical and diagnostic perspective from China", Mycopathologia, 185, pp.599~606 (2020)
- Mahalaxmi I, "Mucormycosis : An opportunistic pathogen during COVID-19", Environ Res, 201, pp.111643~ (2021)
- Prakash H, "Global epidemiology of mucormycosis", J Fungi, 5, pp.26~ (2019)
- Reid G, "Mucormycosis", Semin Respir Crit Care Med, 41, pp.99~114 (2020)
- Skiada A, "Epidemiology and diagnosis of mucormycosis : An update", J Fungi, 6, pp.265~ (2020)
- Agarwal V, "Association of COVID-19 with rhino-cerebral mucormycosis : an observational study", J Maxillofac Oral Surg, 21, pp.990~994 (2022)
- Chavda VP, "Mucormycosis-An opportunistic infection in the aged immunocompromised individual : a reason for concern in COVID-19", Maturitas, 154, pp.58~61 (2021)
- Alekseyev K, "Rhinocerebral mucormycosis and COVID-19 pneumonia", J Med Cases, 12, pp.85~ (2021)
- Hosseini SMS, "Rhinocerebral mucormycosis : pathways of spread", Eur Arch Otorhinolaryngol, 262, pp.932~938 (2005)
- Heard KL, "COVID-19and fungal superinfection", Lancet Microbe, 1, pp.e107~ (2020)
- Nehara HR, "Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio : case series from the north-western part of India", Indian J Med Microbiol, 39, pp.380~383 (2021)
- Singh G, "Neurological manifestations of rhinooculo-cerebral mucormycosis in the COVID-19 era", Nat Rev Neurol, 17, pp.657~658 (2021)
- Garg D, "Coronavirus disease(Covid-19)associated mucormycosis(CAM) : case report and systematic review of literature", Mycopathologia, 186, pp.289~298 (2021)
- Gupta R, "COVID-19 associated mucormycosis : A descriptive multisite study from India", Diabetes Metab Syndr, 15, pp.102322~ (2021)
- Singh AK, "Mucormycosis in COVID-19 : A systematic review of cases reported worldwide and in India", Diabetes Metab Syndr, 15, pp.102146~ (2021)
- Muthu V, "Epidemiology and pathophysiology of COVID-19-associated mucormycosis : India versus the rest of the world", Mycopathologia, 186, pp.739~754 (2021)
- Arora U, "Risk factors for Coronavirus diseaseassociated mucormycosis", J Infect, 84, pp.383~390 (2022)
- Haghani I, "Mucormycosis : A lethal phenomenon in COVID-19 patients : A review of diagnostic and therapeutic approaches", J Mazandaran Univ Med Sci, 1, pp.115~132 (2022)